Study: Statins may stem tumor growth
Human lymphatic endothelial cells on a microscopic micro carrier bead build so-called sprouts (microscopic image). Credit: Martin Schulz/ETH Zurich/PNAS
(Medical Xpress)—One of the world's top selling drugs potentially also acts against the growth of new lymphatic vessels, with potential implications for cancer therapy. This surprising finding was brought forward by Swiss researchers with their newly developed three-dimensional cell culture system.
Researchers at the Institute of Pharmaceutical Sciences at ETH Zurich and the University of California Berkeley have made an unexpected discovery. Their search for novel pharmaceuticals that might prevent the generation of tumour metastases and transplant rejection identified a well-known drug class: the statins. These cholesterol-lowering compounds are standardly used to treat patients with cardiovascular disease to prevent the progression of atherosclerosis. Statins are among the most widely prescribed drugs worldwide.
Scientists led by Michael Detmar, Professor at the ETH Zurich Institute of Pharmaceutical Sciences, made this discovery with a newly developed cell culture system that allows compound screening for modulators of lymphatic vessel expansion. Lymphatic vessel growth is a contributing factor to the dissemination of tumour cells in cancer patients and the rejection of transplanted organs by the recipient's immune system. For their screening system, the researchers coated lymphatic endothelial cells from human skin onto microscopic micro carrier beads consisting of a natural polymer and encapsulated them in a tumour environment mimicking hydrogel. When stimulated with growth factors, the lymphatic endothelial cells started to build so-called sprouts, the first step for the formation of new lymphatic vessels.
Automated cell culture in 3D
To distinguish it from common cell culture methods, which consist of a two-dimensional cell layer in a plane cell culture dish, the researchers called their micro carrier bead system a three-dimensional system that enabled them to test over 1000 small chemical compounds.
"We were able to screen such a high number of substances because we succeeded in automating this process", explains Postdoc Martin Schulz, the first author of the respective study published in the science journal "PNAS". For this work, the researchers utilised an automated screening microscope at the Light Microscopy Centre of ETH Zurich. This approach resulted in over 100'000 high-resolution images of the cell-coated micro beads that visualise the development of sprouts. The sprout number was determined by an algorithm developed by ETH-researcher Felix Reisen from the group of Gisbert Schneider, Professor of Computer-Assisted Drug Design at the Institute of Pharmaceutical Sciences. "Manual analysis would allow a throughput of maybe ten compounds, but impossibly 1000", Schulz states.
System might allow reduction of animal experiments
By utilizing known substances that inhibit lymphatic vessel growth, the researchers demonstrated that the results of their 3D-system are in closer agreement with animal experiments than commonly used cell culture test systems. "Our system thereby offers a better predictability", concludes Michael Detmar. "And in contrast to animal experiments, we are able to directly assess the response in human cells", adds Martin Schulz. The researchers are convinced that the number of animal experiments can be reduced with such a 3D-system, in particular with regard to the pharmacological testing of large numbers of chemical substances.
Scheme of lymphatic vessel sprouting in vivo and the newly developed three-dimensional cell culture system. Addition of the statin Simvastatin or of another inhibitory drug blocks sprouting. Credit: Martin Schulz/ETH ZurichThe so-called screening of over 1000 substances resulted in around 30 compounds that inhibit lymphatic vessel growth. Among several identified pharmaceuticals that were not known to convey this effect, two were investigated in more detail. One of the two – as earlier mentioned – belongs to the drug class of statins. Subsequently, the researchers confirmed the inhibitory effect of statins also in mice.
No suitable medicine available
The researchers consider it possible that statins in the future might not only be administered to patients with cardiovascular disease, but also to cancer patients. Many cancers spread over the body via lymphatic vessels, as has been known for some time – also based on research in the group of Michael Detmar among others. Some tumours are known to secrete mediators that induce the growth of lymphatic vessels towards the tumour. Therefore, clinical oncology has an interest in drugs that inhibit this growth. "So far, there are no reliable treatments available in the clinics", elaborates Detmar.
"In the future, one might imagine to treat high risk cancer patients with statins to prevent developing tumours from metastasizing, even before the cancer diagnosis", says Detmar. Because of their extensive medical evaluation and market approval for other diseases, these drugs would require repurposing by the regulatory authorities for the application as inhibitors of lymphatic vessel growth. This process would be significantly easier than the approval of a new drug.
Fewer tumours after statin treatment
The assumption that the development and progression of tumours might be impeded by statins is supported by a study published 5 weeks ago by researchers at the University Hospital Zurich that the ETH-researchers did not contribute to. There, cancer malignancies of over 100 patients that received a donor heart within the last 20 years were investigated. Patients under continuous statin treatment developed cancer less frequently and had an improved prognosis compared to patients without statins.
Potentially, statins might also be indicated after organ transplantation to reduce graft rejection in future. It is known that immune cells which are mediating organ rejection are transported via lymphatic vessels, and there are studies indicating that graft rejection can be reduced if the growth of lymphatic vessels is inhibited. However, according to Detmar, it is imperative to first investigate whether the commonly applied statin dosages are sufficient to reduce growth of lymphatic vessels in humans.
More information: Schulz MMP, Reisen F, Zgraggen S, Fischer S, Yuen D, Kang GJ, Chen L, Schneider G, Detmar M: Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis. Proceedings of the National Academy of Sciences 2012, in press.
Fröhlich GM et al.: Statins and the Risk of Cancer After Heart Transplantation. Circulation 2012, 126: 440-447. DOI: 10.1161/circulationaha.111.081059
Provided by ETH Zurich
- Evidence strengthens link between NSAIDs and reduced cancer metastasis Feb 13, 2012 | not rated yet | 0
- Chronic skin inflammation alleviated with lymphatic vessel growth stimulation Sep 20, 2010 | not rated yet | 0
- Outsmarting cancer cells: Scientists learn how they spread Apr 08, 2011 | not rated yet | 0
- Migration alert -- How tumor cells home in on the lymphatic system Jun 11, 2007 | not rated yet | 0
- Lymphatic vessel and lymph node function are restored with growth factor treatment Dec 03, 2007 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer May 24, 2013 | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer May 24, 2013 | 5 / 5 (1) | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer May 24, 2013 | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer May 24, 2013 | 5 / 5 (2) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer May 24, 2013 | 5 / 5 (4) | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
18 hours ago | 5 / 5 (5) | 5
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
10 hours ago | not rated yet | 1
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
18 hours ago | 5 / 5 (1) | 1
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
18 hours ago | not rated yet | 0
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
18 hours ago | not rated yet | 0